Safety and pharmacokinetics of bevirimat (PA-457), a novel inhibitor of human immunodeficiency virus maturation, in healthy volunteers

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 9, 2007, Pages 3063-3066

  Martin, David E ^a   Blum, Robert ^b   Wilton, John ^c   Doto, Judy ^a   Galbraith, Hal ^d   Burgess, Gina L ^d   Smith, Philip C ^e   Ballow, Charles ^b  

^a Panacos Pharmaceuticals   (United States)

^b Buffalo Clinical Research Center   (United States)

^c Emprexe Analytical LLC   (United States)

^d IQVIA   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 O (3,3 DIMETHYLSUCCINYL)BETULIC ACID; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; HEADACHE; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NORMAL HUMAN; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; VIRUS INHIBITION; VOLUNTEER;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HUMANS; MALE; MIDDLE AGED; SUCCINATES; TRITERPENES;

EID: 34948903088     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01391-06     Document Type: Article

References (13)

1. Blaise, P., P. Clevenbergh, D. Vaira, M. Moutschen, and P. Dellamonica. 2002. HIV resistance to antiretroviral drugs: mechanisms, genotypic and phenotypic resistance testing in clinical practice. Acta Clin. Belg. 57:191-201.
2. Hogg, R. S., K. V. Heath, B. Yip, K. J. Craib, M. V. O'Shaughnessy, M. T. Schechter, and J. S. Montaner. 1998. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 279:450-454.
3. Kilgore, N., M. Reddick, M. Zuiderhof, F. Li, Y. Abdul, C. Matallana, D. Zoumplis, A. Castillo, K. Salzwedel, and C. Wild. 2006. Abstr. 13th Conf. Retrovir. Opportunist. Infect., abstr. 509.
4. LaBonte, J., J. Lebbos, and P. Kirkpatrick. 2003. Enfuvirtide. Nat. Rev. Drug Discovery 5:345-346.
5. Li, F., R. Goila-Gaur, K. Salzwedel, N. R. Kilgore, M. Reddick, C. Matallana, A. Castillo, D. Zoumplis, D. E. Martin, J. M. Orenstein, G. P. Allaway, E. O. Freed, and C. T. Wild. 22 October 2003, posting date. A new class of potent HIV inhibitors disrupts core condensation by targeting a late step in gag processing. Proc. Natl. Acad. Sci. USA doi:10.1073/pnas.2234683100.
6. Martin, D. E., P. Smith, R. Goila-Gaur, K. Salzwedel, F. Li, N. Kilgore, M. Reddick, C. Matallana, A. Castillo, D. Zoumplis, G. Allaway, E. Freed, and C. Wild. 2004. Abstr. 11th Conf. Retrovir. Opportunist. Infect., abstr. 545.
7. Martin, D. E., C. H. Ballow, R. Blum, J. Doto, C. T. Wild, and G. P. Allaway. 2005. Abstr. 12th Conf. Retrovir. Opportunist. Infect., abstr. 551.
8. Molina, J. M., G. Peytavin, S. Perusat, C. Lascoux-Combes, D. Sereni, W. Rozenbaum, and G. Chene. 2004. Pharmacokinetics of emtricitabine, didanosine and efavirenz administered once-daily for the treatment of HIV-infected adults (pharmacokinetic substudy of the ANRS 091 trial). HIV Med. 5:99-104.
9. Palella, F. J., Jr., K. M. Delaney, A. C. Moorman, M. O. Loveless, J. Fuhrer, G. A. Satten, D. J. Aschman, S. D. Holmberg, et al. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338:853-860.
10. Richman, D., S. Morton, T. Wrin, N. Hellmann, S. Berry, F. Shapiro, and S. Bozzette. 2004. The prevalence of antiretroviral drug resistance in the United States. AIDS 18:1393-1401.
11. Smith, P. C., J. Hasegawa, P. N. J. Langendijk, and L. Z. Benet. 1985. Stability of acyl glucuronides in biological fluids: studies with zomepirac. Drug Metab. Dispos. 13:110-112.
12. Smith, P. F., A. Ogundele, A. Forrest, and D. E. Martin. 2005. Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother., abstr. A-1149.
13. Wen, Z., S. T. Stern, D. E. Martin, K. H. Lee, and P. C. Smith. 2006. Structural characterization of anti-HTV drug candidate PA-457 [3-O-(3′,3′-dimethylsuccinyl)-befulinic acid] and its acyl glucuronides in rat bile and evaluation of in vitro stability in human and animal liver microsomes and plasma. Drug Metab. Dispos. 34:1436-1442.